Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
Clinical trial NCT02887248 · TERMINATED
Trial details
- NCT number
- NCT02887248
- Sponsor
- SCRI Development Innovations, LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-12
- Primary completion
- 2020-05-01
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.